2 drugs are better than 1 at targeting tumors with B-RAF mutations
Friday, October 24, 2008 - 05:07
in Health & Medicine
In a proportion of human solid tumors, in particular melanomas (a form of skin cancer that is often resistant to chemotherapy), inappropriate activation of the MEK/ERK signaling pathway as a result of mutations in the B-RAF gene promotes tumor cell growth and survival. Although MEK inhibitors stop such tumor cells growing, they have a limited ability to kill the tumor cells. Thus, they have had limited success in promoting tumor regression in preclinical and clinical trials.
Read the whole article on Physorg
More from Physorg
Related
- 2 drugs are better than 1 at targeting tumors with B-RAF mutationsFri, 24 Oct 2008, 6:08:40 EDT
- Preventing tumor cells from refueling: A new anti-cancer approach?Thu, 20 Nov 2008, 17:57:20 EST
- Combining targeted therapy drugs may treat previously resistant tumorsSun, 30 Nov 2008, 14:07:42 EST
- Revolutionary drug could be new hope for adrenal cancer patientsTue, 22 Sep 2009, 12:50:19 EDT
- New cancer treatment targets both tumor cells and blood vesselsWed, 18 Jun 2008, 12:21:21 EDT